NLRP3 and diabetes mellitus: Other studies have confirmed that glibenclamide and metformin, both of which are typical treatments for diabetes, have the potential to inhibit the activation of the NLRP3 inflammasome, indirectly indicating that the NLRP3 inflammasome is associated with T1DM.